The Department of Surgery at the University of Texas Medical School at Houston
Department of Surgery
Division of Urology

Faculty Profile

Steven E. Canfield M.D.

Associate Professor
Division of Urology
Department of Surgery

Chief of Urology
Lyndon B. Johnson General Hospital


Steven E. Canfield M.D. is an Associate Professor of Surgery in the Division of Urology. Dr. Canfield is board certified in Urology and fellowship trained in Urologic Oncology by MD Anderson Cancer Center. His specialties include prostate cancer and robotic surgery, bladder cancer and kidney cancer.

Undergraduate Education

1992 B.S. - Haverford College Major: Biology (Honors)

Graduate Education

1996 M.D. - Jefferson Medical College

POSTGRADUATE TRAINING

07/96-06/98, Intern & Junior Resident, Dept. of Surgery, Mt. Sinai School of Medicine, New York, NY.

07/98-06/02, Resident & Chief Resident, Dept. of Urology, Mt. Sinai School of Medicine, New York, NY.

07/02-06/05, Fellow, Urologic Oncology, MD Anderson Cancer Center, Houston, TX.

06/06-07/06, Mini-Fellowship, Robotic Assisted Radical Prostatectomy, University of Pennsylvania, Philadelphia, PA, Mentor: David Lee, MD

ACADEMIC APPOINTMENTS

Associate Professor
Division of Urology, Department of Surgery
The University of Texas Medical School at Houston, Houston TX 
September 2011 to present

Assistant Professor
Division of Urology, Department of Surgery
The University of Texas Medical School at Houston, Houston TX 
August 2005 to August 2011

Chief of Urology
Lyndon B. Johnson General Hospital
Harris County Health District
Houston TX
August 2006 to present

Adjunct Assistant Professor
Department of Urology
The University of Texas MD Anderson Cancer Center
Houston TX
August 2005 to November 2007

Associate Professor
Department of Urology
The University of Texas MD Anderson Cancer Center
Houston TX
September 2011 to present

Assistant Professor
Department of Urology
The University of Texas MD Anderson Cancer Center
Houston TX
December 2007 to August 2011

Director, Residency Program
Division of Urology, Department of Surgery
The University of Texas Medical School at Houston, Houston TX 
January 2010 to present

HOSPITAL APPOINTMENTS

08/05-present, Memorial Hermann Hospital
08/05-present, Lyndon B. Johnson General Hospital
08/05-present, MD Anderson Cancer Center

LICENSURE

New York State Medical License: 210496 - inactive
Pennsylvania State Medical License: MD428546-inactive
Texas State Medical License: L9123
Florida State Medical License: ME99268

CERTIFICATIONS

Diplomate, American Board of Urology
Certification Exam, Part II
December 2007

American Board of Urology
Certification Exam, Part I
June 2002

Diplomate, National Board of Medical Examiners
July 1997

PROFESSIONAL ORGANIZATIONS

Regional: 

South Central Section of the AUA, 2005
Southwest Oncology Group, 2006

National: 

American Urology Association, 1998
Society of Urologic Oncology, 2005

International:

International Evidence Based Urology Working Group, 2008

HONORS AND AWARDS

1991:  Merck Summer Science Research Fellow

1996:  The Paul D. Zimskind Memorial Prize in Urology, Dept. of Urology, Jefferson Medical College

2000:  The Ferdinand C. Valentine Essay Contest - Third Prize - Basic Science

2001:  The Ferdinand C. Valentine Essay Contest - Second Prize - Basic Science

2002:  The Praecis Scholar Award

2004:  The AACR Scholar-in-Training Award

2006:   The LBJ General Hospital Outpatient Clinic - “Best patient satisfaction” Award

2010:  Dean’s Teaching Excellence Award - UT Medical School at Houston

2011:  Dean’s Teaching Excellence Award - UT Medical School at Houston

EDITORIAL POSITIONS: 

2005:   Urologic Oncology - reviewer
2006:   Urology - reviewer
2007:   Surgical Oncology - reviewer
2008:   Journal of Urology - reviewer
2008:   Medscape Journal of Urology – reviewer
2008:   AUA Office of Education – content reviewer
2009:  McMaster Online Rating of Evidence (MORE) – content reviewer
2009:  British Journal of Urology International - reviewer
2009:  Practical Reviews in Urology – contributing editor
2009:  Evidence Based Reviews in Urology – steering committee, content developer and session moderator
2010:  Series Editor, “Advanced Topics in Evidence-Based Urologic Oncology”, Urologic Oncology

COMMITTEE AND COMMUNITY SERVICE:

UT-HMS COMMITTEES:

Faculty Senate, 2009 – present

UT-HMS AFFILIATED HOSPITALS COMMITTEES

HCHD Cancer Committee, 2006-present
Memorial Hermann Hospital Cancer Committee, 2006-07     
LBJGH Executive Committee, 2007-present
LBJGH Chief’s Committee, 2007-present
LBJGH OR Committee, 2007-present
LBJGH Oncology Steering Committee, 2008-present
HCHD Medical Executive Board, 2008-present
HCHD Ambulatory Care Committee, 2009-present
Chair: subcommittee on patient no-shows
HCHD Credentialing Committee, 2010 – present

COMMUNITY SERVICE

Jobs in our community, Becker Pre-School, 2008 and 2009

Learning about our community: How Doctors Help, Roberts Elementary School, 2010, 2011

Day in the District, LBJGH, 2009 - present

Temple Emanuel Brotherhood, committee member, Congregation Emanu El, 2009 – present

Temple Emanuel, Mitzvah Day volunteer, Congregation Emanu El, 2009 – present

CURRENT TEACHING RESPONSIBILITIES

Faculty, Division of Urology, Department of Surgery, University of Texas Medical School at Houston
Daily clinical and surgical resident training teaching duties, August 2005 - present

Course Director, Monthly Resident Research Conference, Division of Urology, Department of Surgery,
University of Texas Medical School at Houston, Organized and oversaw monthly research lectures with guest speakers for the Urology residency, August 2005 – June, 2007

Trainee, Teaching and Leading EBM: A Workshop for Teachers and Champions of Evidence-Based Medicine, DUKE Program on Teaching EBM, DUKE University Medical Center, Role: participant in one of the most prominent EBM workshops in the country, April 22-25, 2008

Facilitator, EBM Workshop for Chief Residents, University of Texas Medical School at Houston
2 half-day (4 hour) sessions teaching the basics of literature appraisal as a workshop faculty member to UT chief residents from all disciplines (approx 30 learners), May 22-23, 2008

Course Director, Urology Residency Evidence-Based Medicine Curriculum, Division of Urology, Department of Surgery, University of Texas Medical School at Houston Curriculum includes didactic lectures (approximately 4 lectures / year 1 hour each), monthly EBM case presentations (30 minute mentored resident presentations), monthly EBM journal clubs (90 minutes) and online EBM related material and modules (monthly 30 minute appraisal exercises)., August 2008 – present

Facilitator, Literature Appraisal Course, Clinical Research Curriculum, University of Texas Medical School at Houston, 6 x 1.5 hour hands-on sessions teaching literature appraisal with different article types to UT CRC students (approx 20 learners per group), December, 2008 – February, 2009

Course Co-Faculty, Evidence Based Decision-Making in Urology: How to Find and Apply the Best Evidence in Caring for Your Patients, AUA Annual Meeting, Chicago, Illinois, 1 of 3 course leaders. 4 hour course designed to introduce and teach the basics of EBM to a Urological audience. The AUA annual meeting is the largest international meeting of its kind and courses must be submitted to and approved by the AUA Office of Education. Approximately 40 urologists attend the course each year., April 26, 2009

Facilitator, EBM Workshop for Chief Residents, University of Texas Medical School at Houston
2 half-day (4 hour) sessions teaching the basics of literature appraisal as a workshop faculty member to UT chief residents from all disciplines (approx 30 learners)., June 15-16, 2009

Trainee, Teaching Evidence Assimilation, GRADE workshop, New York Academy of Medicine, New York, NY, Role: participant in a workshop on GRADE guideline development methodology and use., August 11-15, 2009

Preceptor, MS III surgical sub-specialty rotation in Urology, UT Medical School at Houston, LBJGH rotation, Primary supervising attending for third-year medical students rotating for 4 week blocks on the LBJ Urology service, where they are instructed on basics of urological clinical and operative care., July 2009 – present

Faculty, Evidence Based Reviews in Urology (EBRU), Online EBM Journal Club, www.AUAnet.org
8 monthly sessions reviewing seminal articles in Urology, with attention to methodological quality as well as clinical content. Faculty serve as session moderators (1 month) and content developers. The program is available to the entire international Urological community. There are over 250 participants each year., September, 2009 – April, 2010

Faculty, Apex MS2MD course, Baylor College of Medicine, Houston, TX, “Minimally Invasive EBM”, 1.5 hour workshop teaching practical EBM skills to graduating medical students going into surgical fields (approximately 50 students), March 03, 2010

Faculty, CABS EBM course, Baylor College of Medicine, Houston, TX, 8 weekly 2.5 hour sessions given by the 6 faculty members. Personal lectures: “Stats and Epidemiology I “ and “Stats and Epidemiology II”. This course is the main evidence-based medicine course for the Baylor medical school curriculum, taught in the second year. In addition to individual lectures, faculty members participate in each lecture as a facilitator during small group sessions. (Approximately 150 students), March 11 – April 29, 2010

Course Co-Faculty, Evidence-Based Guidelines, A Workshop for Guideline Developers, European Association of Urology Annual Meeting, Barcelona, Spain, 1 of 3 course leaders. This 4 hour workshop to train current guideline developers for the European Association of Urology (EAU) was commissioned by the EAU Guideline Committee. I was invited to be one of 3 international workshop leaders. (Approximately 50 international participants)., April 16, 2010

Course Co-Faculty, Evidence-Based Decision Making in Urology: Assessing the Quality of Evidence Using GRADE, AUA Annual Meeting, San Francisco, California, 1 of 3 course directors. 4 hour course designed to introduce and teach the basics of EBM using the GRADE system to a Urological audience. The AUA annual meeting is the largest international meeting of its kind and courses must be submitted to and approved by the AUA Office of Education. The course was modified significantly this year to introduce the GRADE system, an internationally recognized method for guideline development. Approximately 40 urologists attend the course each year., May 30, 2010

Faculty, Prostate Cancer: Updates, Advances and Future Directions, Educational Concepts Group, Atlanta, GA, Content development, validation and national lecturer for this continuing education series supported by an educational grant. Multiple 1 hour lectures to approximately 40 participants per lecture., March – December 2010

Facilitator, EBM Workshop for Chief Residents, University of Texas Medical School at Houston, 2 half-day (4 hour) sessions teaching the basics of literature appraisal as a workshop faculty member to UT chief residents from all disciplines (approx 30 learners)., May 5-6, 2010

Program Director, Urology Residency, University of Texas Medical School at Houston, 12 resident program with 6 affiliated sites. Responsible for the education and training of the residents and the well being of the program. Occupies approximately 20% of time., January 1, 2010 – present

Mentor, UT MS IV pursuing research interests in Urology, Gavin Wagenheim, 2010 – Harris County Prostate Cancer Disparities Project (database project with over 6,000 patients), Patrick Cockerill, 2010 – Harris County Bladder Cancer Disparities Project (database project with over 1,000 patients. Abstract accepted for presentation at the 2011 AUA Annual Meeting.)

Mentor, UT Urology Residents pursuing Urologic Oncology Fellowships, Jennifer Taylor, 2009 – Memorial Sloan Kettering Cancer Center, Anthony Hoang, 2011 – National Institute of Health

Faculty, Evidence Based Reviews in Urology (EBRU), Online EBM Journal Club, www.AUAnet.org, 8 monthly sessions reviewing seminal articles in Urology, with attention to methodological quality as well as clinical content. Faculty serve as session moderators (1 month) and content developers. The program is available to the entire international Urological community. There are over 250 participants each year., September, 2010 – April, 2011

Facilitator, Literature Appraisal Course, Clinical Research Curriculum, University of Texas Medical School at Houston, 6 x 1.5 hour hands-on sessions teaching literature appraisal with different article types to UT CRC students (approx 20 learners per group)., January, 2011 – February, 2011

Faculty, Apex MS2MD course, Baylor College of Medicine, Houston, TX, “Minimally Invasive EBM” 1.5 hour workshop teaching practical EBM skills to graduating medical students going into surgical fields (approximately 50 students)., March 02, 2011

Faculty, CABS EBM course, Baylor College of Medicine, Houston, TX, 9 weekly 2.5 hour sessions given by the 6 faculty members. Personal lectures: “Stats and Epidemiology I “ and “Stats and Epidemiology II”. This course is the main evidence-based medicine course for the Baylor medical school curriculum, taught in the second year. In addition to individual lectures, faculty members participate in each lecture as a facilitator during small group sessions. (Approximately 150 students)., March 10 – May 12, 2011

Course Co-Director, Evidence-Based Guidelines: A Workshop for Guideline Developers, European Association of Urology Annual Congress, Vienna, Austria, 1 of 2 course directors. This 4 hour workshop to train current guideline developers for the European Association of Urology (EAU) was commissioned by the EAU Guideline Committee in 2010. The Board of Directors voted to continue the workshop again based on positive reviews. I was one of 4 international workshop leaders. (Approximately 100 active EAU Guideline panel members were in attendance)., March 18, 2011

Course Director: How to Practice Evidence-Based Urology, European Association of Urology Annual Congress, Vienna, Austria, This new course was approved by the European School of Urology (ESU), the educational arm of the EAU, for presentation at this year’s international congress. The course is a 3 hour workshop on the basics of EBM, designed for a urological audience., March 21, 2011

Course Co-Faculty, Evidence-Based Decision Making in Urology: Assessing the Quality of Evidence Using GRADE, AUA Annual Meeting, Washington, DC, 1 of 3 course leaders. This annual course was once again approved by the AUA office of education. It remains the only EBM course offered by the AUA. The 4 hour course is designed to introduce and teach the basics of EBM using the GRADE system to a Urological audience. The AUA annual meeting is the largest international urology meeting in the world. Approximately 40 urologists attend the course each year., May 18, 2011

Faculty, Evidence Based Reviews in Urology (EBRU), Online EBM Journal Club, www.AUAnet.org, 8 monthly sessions reviewing seminal articles in Urology, with attention to methodological quality as well as clinical content. Faculty serve as session moderators (1 month) and content developers. The program is available to the entire international Urological community. There are over 250 participants each year., October, 2011 – May, 2012

GRANT SUPPORT:

Current Grant Support

Role: Co-Investigator
Title: Clinical Study to Evaluate the Ability of Muse to Decrease Erectile Function Recovery Time in Post-Radical Prostatectomy Patients
Primary Investigator: Run Wang, MD, FACS
Funding Agency: VIVUS, Inc.
Award Period: 3/10/06 – present
Amount: $117,655.89

Role: Site Primary Investigator Title: Prostate Serum/Tissue Bank in Underserved Minority Populations
Primary Investigator: Curtis Pettaway, MD
Funding Agency: CDC
Award Period: 9/30/06 – 9/29/08
Amount: $71,201.00

Role: Co-Investigator
Title: HSC-MS-07-0059 - LBJ Patient History Database - Serum/DNA Bank
Primary Investigator: Karin Hahn, MD
Funding Agency:
Award Period: 2/07/08 – present
Amount: TBD

Role: Co-Investigator
Title: Premature ejaculation study
Primary Investigator: Run Wang, MD
Funding Agency:
Award Period: January 2008 - present
Amount: TBD

Role: Primary Investigator
Title: LBJ Clinical Research Outreach Program in Urologic Oncology
Funding Agency: University Cancer Fund, MDACC
Award Period: September 2008 – August 2009
Amount: $82,000

Role: Co-Investigator
Title: Clinical Study to Evaluate the Ability of Muse to Decrease Erectile Function Recovery Time in Post-Radical Prostatectomy Patients
IRB: HSC-MS-05-0425
Primary Investigator:  Run Wang, MD, FACS
Funding Agency: VIVUS, Inc.
Award Period:  3/10/06 – present
Amount: $117,655.89

Role: Co-Investigator
Title: LBJ Patient History Database - Serum/DNA Bank
IRB: HSC-MS-07-0059
Primary Investigator: Karin Hahn, MD    
Funding Agency: MDACC Uncompensated Charity Care Program
Award Period: 2/07/08 – present
Amount: N/A

Role: Co-Investigator
Title: The Brief Sleep Disturbance Scale: Measuring Sleep Disturbance Among Cancer Patients
IRB: HSC-GEN-09-0661
Primary Investigator: Karin Anderson, MD
Funding Agency: Internal, MDACC
Award Period: N/A
Amount: N/A

Role: Co-Investigator
Title: Identification and Treatment of Depression in Underserved African American and Latino Patients with Cancer
IRB: HSC-GEN-08-0633
Principle Investigator: Karin Anderson, MD
Funding Agency: Internal, MDACC
Award Period: N/A
Amount: N/A

Role: Primary Investigator
Title: A Pilot Study of Aurolase Therapy in Patients with Late Stage Prostate Cancer- Systemic Delivery
IRB: HSC-MS-09-0611
Funding Agency: Nanospectra Biosciences Inc.
Award Period: TBD by FDA
Amount: TBD pending FDA approval

Role: Co-Primary Investigator
Title: GI and Genitourinary(GU) Cancer (Urinary Bladder, Kidney/Renal, Adrenal, Ureter, Urethra, Testiscular, Prostate) Database for Harris County Hospital District (HCHD)
IRB: HSC-MS-08-0535
Primary Investigator: Curtis Wray, MD
Funding Agency: N/A
Award Period: N/A
Amount: N/A

Role: Co-Investigator
Title: Using Wikis to Improve the Dissemination, Evaluation, and Application of Evidence-Based Medicine in Surgical Practice
Principle Investigator: Lillian Kao, MD
Funding Agency: The University of Texas Academy of Health Science Education Small Grants Program
Award Period: February 2010 – February 2011
Amount: $5,000

Role: Principal Investigator
Title: Impact of AUREON’s Prostate PX on Clinician Recommendations for Patients Newly Diagnosed
Funding Agency: AUREON Biosciences, Inc.
Award Period: October 1, 2011 to present
Amount: $77,398

Past Grant Support

Role: Site Primary Investigator                                                     
Title: Prostate Serum/Tissue Bank in Underserved Minority Populations   
Primary Investigator: Curtis Pettaway, MD
Funding Agency: CDC
Award #5H75ccH624031 02 (PP1)
Award Period: 9/30/06 – 9/29/08
Amount: $71,201.00

Role: Primary Investigator
Title: LBJ Clinical Research Outreach Program in Urologic Oncology
Funding Agency: University Cancer Fund, MDACC
Award Period: September 2009 – August 2011
Amount: $82,000 per year
Role: Co-Primary Investigator
Title: Screening for Bladder Cancer
IRB: HSC-MS-10-0018
Funding Agency: National Cancer Institute
Award Period: 09/01/2010 – 08/31-2011
Amount: $639,084

INVITED PRESENTATIONS:

1. Clinical surveillance after radical nephrectomy. Presented at the Kidney Cancer Association Survivor and Patient conference, Houston, TX, September 10, 2005.

2. Current Topics in Testicular Cancer. Presented at the Current Advances in Urology – A Symposium for Chinese University Urologist Training College, Houston, TX, May 16, 2006.

3. The Role of Metastasectomy for Renal Cell Carcinoma. Presented at the Kidney Cancer Association Survivor and Patient Conference, Houston, TX, January 9, 2007.

4. Prostate Cancer Treatment 2007 – State of the Art: Proton Radiation and Robotic Surgery. Presented at the MD Anderson Pelvic Health Seminar, Houston, TX, September 20, 2007.

5. Urology: A Comprehensive Overview. Presented at the Surgical Student Lecture Series UT Medical School, Houston, TX, October 11, 2007.

6. Hematuria: An Evidence Based Approach to the Urological Work-up. Presented at the Internal Medicine Resident Noon Conference, UT Medical School, Houston, TX, October 25, 2007.

7. Clinical Research in Genitourinary Oncology at LBJ General Hospital: Challenges and Opportunities. Presented at the Genitourinary Cancer Conference, MD Anderson Cancer Center, Houston, TX, May 2008.

8. The Evidence for Localized Prostate Cancer. Presented at Family and Community Medicine Grand Rounds, UT Medical School, Houston, TX, June 4, 2008.

9. Prediction and Treatment of Localized Prostate Cancer Using Evidence Base Medicine. Presented at the Division of Urology Grand Rounds, UT Medical School at Houston, TX, July 10, 2008.

10. Minimally Invasive New Technology in Oncologic Surgery: Urology Report. Presented at the MINTOS Conference, MD Anderson Cancer Center, Houston, TX, July, 2008.

11. Localized Prostate Cancer: A Perspective on Evidence Based Clinical Practice. Presented at General Surgery Grand Rounds, UT Medical School, Houston, TX, July 31, 2008.

12. Can Prostate Cancer Be Prevented? Presented at the Prostate Cancer Awareness Conference, MD Anderson Cancer Center, Houston, TX, September 11, 2008.

13. Role of Lymph Node Dissection in the Surgical Management of Renal Cell Carcinoma. Presented at the Urologic Oncology: Advances in Clinical Practice seminar, MD Anderson Cancer Center, Houston, TX, October 25-26, 2008.

14. Evidence Based Medicine in Localized Prostate Cancer. Presented at the Genitourinary Program Grand Rounds, H. Lee Moffitt Cancer Center, Tampa, FL, December 1, 2008.

15. Localized Prostate Cancer: A Perspective on Evidence Based Clinical Practice. Presented at Urology Grand Rounds, Tulane University Medical School, New Orleans, LA, January 19, 2009.

16. Appraisal of a Randomized Controlled Trial. Presented at the Evidence Based Decision-Making in Urology: How to Find and Apply the Best Evidence in Caring for Your Patients course, AUA Annual Meeting, Chicago, Illinois, April 26, 2009.

17. Evidence Based Medicine for Prostate Cancer. Presented at Internal Medicine Grand Rounds, UT Medical School, Houston, TX, June 30, 2009.

18. Minimally Invasive EBM. Presented at the APEX: MD2MS course, Baylor College of Medicine, Houston, TX, March 3, 2010.

19. Statistics and Epidemiology I. Presented at the CABS EBM Course, Baylor College of Medicine, Houston, TX, March 25, 2010.

20. Statistics and Epidemiology II. Presented at the CABS EBM Course, Baylor College of Medicine, Houston, TX, April 1, 2010.

21. Formulating a Clinical Question, Searching, and Ranking Outcomes. Presented at the Evidence Based Guidelines, A Workshop for Guideline Developers Workshop, European Association of Urology Annual Meeting, Barcelona, Spain, April 16, 2010.

22. GRADE Criteria: Limitations of Study Design. Presented at the Evidence-Based Decision Making: Assessing the Quality of Evidence Using GRADE course, American Urological Association Annual Meeting, San Francisco, CA, May 30, 2010.

23. How do I Appraise the Literature? Presented at the Summer Student Research Lecture Series, Department of Surgery, UT Medical School at Houston, June 8, 2010.

24. Prostate Cancer: Updates, Advances and Future Directions. Presented for the Educational Concepts Group Continuing Education Series, Mercy Medical Center, Rockville, NY, August 26, 2010.

24. Minimally Invasive EBM. Presented at the APEX: MD2MS course, Baylor College of Medicine, Houston, TX, March 2, 2011.

25. Statistics and Epidemiology I. Presented at the CABS EBM Course, Baylor College of Medicine, Houston, TX, April 14, 2011.

26. Formulating a Clinical Question (PICO). Presented at the Evidence Based Guidelines: A Workshop for Guideline Developers Workshop, European Association of Urology Annual Congress, Vienna, Austria, April 18, 2011.

27. Ranking the Evidence: Factors which Lower or Raise the Quality of Evidence. Presented at the Evidence Based Guidelines: A Workshop for Guideline Developers Workshop, European Association of Urology Annual Congress, Vienna, Austria, April 18, 2011.

28. Formulating a Recommendation: Factors which Help Determine the Strength of a Recommendation. Presented at the Evidence Based Guidelines: A Workshop for Guideline Developers Workshop, European Association of Urology Annual Congress, Vienna, Austria, April 18, 2011.

29. Introduction: What is EBM and how does it apply to Urology? Presented at the How to Practice Evidence Based Urology workshop, European Association of Urology Annual Congress, Vienna, Austria, April 21, 2011.

30. Are the results valid? Presented at the How to Practice Evidence Based Urology workshop, European Association of Urology Annual Congress, Vienna, Austria, April 21, 2011.

31. What are the results? Presented at the How to Practice Evidence Based Urology workshop, European Association of Urology Annual Congress, Vienna, Austria, April 21, 2011.

32. GRADE Criteria: Limitations of Study Design. Presented at the Evidence-Based Decision Making: Assessing the Quality of Evidence Using GRADE course, American Urological Association Annual Meeting, Washington, DC, May 18, 2011.

33. How do I Appraise the Literature? Presented at the Summer Student Research Lecture Series, Department of Surgery, UT Medical School at Houston, June 16, 2011.

34. PSA Screening: Crawling or Crying Towards Clarity? Presented at Family Medicine Grand Rounds, UT Medical School at Houston, July 6, 2011.

35. Evidence Concepts for the Practicing Urologist. Presented at Baylor College of Medicine Department of Urology Grand Rounds, November 30, 2011.

Session Moderator

1. Prostate Cancer Diagnosis. Podium presentation session moderator at the South Central Section of the American Urological Association Annual Meeting, Scottsdale, AZ, October 14, 2009.

2. Prostate Cancer Screening. Session moderator for the Evidenced Based Reviews in Urology online journal club, www.AUAnet.org, December, 2009.

3. General and Epidemiological Trends and Socioeconomics: Evidence Based Medicine and Outcomes. Poster session moderator at the American Urological Association Annual Meeting, San Francisco, CA, May 30, 2010.

4. Prostate Cancer Vaccine Therapy: Session moderator for the Evidenced Based Reviews in Urology online journal club, www.AUAnet.org, December, 2010.

5. Partial versus Radical Nephrectomy for RCC: Session moderator for the Evidence Based Reviews in Urology online journal club, www.AUAnet.org, November, 2011.

PUBLICATIONS:

A. Abstracts:

1. Santer UV, Tate D, Canfield S, Kansil S, and Santer M: Base Changes at Position
529, but not 527 or 528, in 16S RNA are Highly Deleterious for Growth and
Protein Synthesis. FASEB Journal, Abstracts, 7.7: 1093, 1993.

2. Canfield SE, Hassen W, Atkinson G, and Hall SJ: Tumor Cell Expression of Fas
as a Target for Prostate Cancer Gene Therapy. Journal of Urology, 163 (4) Supp.:
37-38, 2000.
Presented at the 2000 annual meeting of the American Urological Association,
April 29 - May 4.

3. Hall SJ, Yan Y, Canfield SE, and Chen S-H: A Role for Fas/FasL Interactions in a
Bystander Effect Following the Combination of Ad.HSV-tk + GCV and Ad.IL-12.
Molecular Therapy, 1 (5) : S128, 2000.

4. Canfield SE, Hassen W, Yan Y and Hall SJ: HSV-TK and IL-12 Gene Therapy
Orchestrate a Bystander Effect Through Fas and FasL Interactions in
Experimental Prostate Cancer. Journal of Urology 165 (5) Supp.: 142, 2001.
Presented at the 2001 annual meeting of the American Urologic Association,
June 2-7.

5. Cohen DD, Canfield SE, Sanchez-Ortiz RF, Madsen LT, Swanson DA and Wood CG: Aggressive Resection for Locally Advanced Renal Cell Carcinoma. Journal of Urology, 169(4) Supp.: 175, 2003.

6. Canfield SE, Williams SA, McConkey DJ: Bortezomib Combined with Docetaxel: Inhibition of Efficacy Via Cell Cycle Arrest in Experimental Prostate Cancer. Minisymposium presentation at the 2004 annual meeting of the American Association for Cancer Research.

7. Canfield SE, Kamat AM, Sanchez-Ortiz RF, Swanson DA and Wood CG: Renal Cell Carcinoma with Nodal Metastases in the Absence of Distant Metastatic Disease (Clinical Stage TXN1-2M0): Predictive Factors for Survival. Journal of Urology 171(4) Supp.: 472, 2004. Presented at the 2004 annual meeting of the American Urologic Association.

8. Kent D, Canfield SE, Troncoso P and Babaian RJ: Comparative Analysis of the Pathologic Features of Biopsy Proven Gleason 8 or Greater Prostate Cancer Between 1991 – 2004. Presented at the 2005 annual meeting of the South Central Section of the American Urologic Association.

9. Kasraeian A, Pendleton J, Wludyka P, Anai S, Nakamura K, Canfield SE, Rosser CJ: Knowledge and Attitudes of Primary Care Physicians Regarding Prostate Cancer Screening. Presented at the 2006 annual meeting of the South Eastern Section of the American Urologic Association.

10. Hoang, A., Holland, M., Refuerzo, J., Mastrobattista, J.M., Frumovitz, M., Canfield, S.E.: Urachal carcinoma during pregnancy: a multi-disciplinary approach. Presented at the Society of Urologic Oncology annual winter meeting, 2008.

11. Holland, M.G., Mastrobattista, J.M., Hoang, A., Frumovitz, M., Canfield, S.E., Refuerzo, J.: Diagnosis of urachal adenocarcinoma during prenatal ultrasound. Presented at the American Institute for Ultrasound in Medicine annual meeting, 2009.

12. McLaughlin, S., Canfield, S.E., Fesperman, S.F., Dahm, P.: Evaluating the evidence: a critical appraisal of the methodological quality of systematic reviews published in the urological literature (1998-2008). Presented at the American Urological Association annual meeting, 2009.

13. Echeverry, E.C., Cockrell, P., Ko, T.C., Wray, C., Kao, L., Canfield, S.E.: Public vs. Private: A Comparison of Bladder Cancer Outcomes in Two Health Care Settings. Presented at the American Urological Association annual meeting, 2011.

B. Refereed Original Articles in Journals

1. Das, A., Strup, S., Canfield, S.E., Mulholland, S.G., Gomella, L.G.: Utilization of autologous blood donation during radical retropubic prostatectomy.
Tech Urol. 4(3):131-135, 1998.

2. Sanford, M.A., Yan, Y., Canfield, S.E., Hassen, W., Selleck, W.A., Atkinson, G., Chen, S.H., Hall, S.J.: Independent contributions of Gr-1+ leukocytes and Fas/FasL interactions to induce apoptosis following interleukin-12 gene therapy in a metastatic model of prostate cancer. Hum Gene Ther. 12(12):1485-1498, 2001.

3. Canfield, S.E., Gans, T.H., Unger, P., Hall, S.J.: Postradiation prostatic sarcoma:
de novo carcinogenesis or dedifferentiation of prostatic adenocarcinoma?
Tech Urol. 7(4):294-295, 2001.

4. Droller, M.J.,Canfield, S.E.: Where we stand with tumor markers for urothelial
malignancy. Contemp Urol. 14(4):63-82, 2002.

5. Hall, S.J., Canfield, S.E., Yan, Y., Hassen, W., Selleck, W.A., Chen S.H.: A novel
bystander effect involving tumor-cell derived Fas and FasL interactions following Ad.HSV-tk and Ad.IL-12 gene therapies in experimental prostate cancer. Gene Ther. 9(8):511-517, 2002.

6. Selleck, W.A., Canfield, S.E., Hassen, W.A., Meseck, M., Kuzmin, A.I., Eisensmith, R.C., Chen, S.H., Hall, S.J.: IFN-gamma sensitization of prostate cancer cells to Fas mediated death: a gene therapy approach. Mol Ther. 7(2):185-92, 2003.

7. Canfield, S.E., Dinney, C.P.N., Droller, M.J.: Surveillance and management of recurrence for upper tract transitional cell carcinoma. Urol Clin North Am. 30(4):791-802, 2003.

8. Sanchez-Ortiz, R.F., Madsen, L.T., Swanson, D.A., Canfield, S.E., Wood, C.G.: Closed suction or penrose drainage after partial nephrectomy: does it matter?
J Urol. 171(1):244-246, 2004.

9. Canfield, S.E., Matin, S.F.: Urologic cancers: when is laparoscopic treatment the standard of care? Contemp Urol. 17(3):38-57, 2005.

10. Canfield, S.E., Kamat, A.M., Sánchez-Ortiz, R.F., Detry, M., Swanson, D.A., Wood, C.G.: Renal cell carcinoma with nodal metastases in the absence of distant metastatic disease (clinical stage TxN1-2M0): the impact of aggressive surgical resection on patient outcome. J Urol., 175(3):864-869, 2006.

11. Canfield, S.E., Zhu, K., Williams, S.A., McConkey, D.J.: Bortezomib inhibits docetaxel-induced apoptosis via a p21-dependent mechanism in human prostate cancer cells. Mol Cancer Ther. 5(8):2043-2050, 2006.

12. Taylor, L.G., Canfield, S.E., Du, X.L.: Review of major adverse effects of androgen deprivation therapy in men with prostate cancer. Cancer, 15(11):2388-2399, 2009.

13. Canfield, S.E.: ACP Journal Club. Annual screening for prostate cancer did not reduce mortality from prostate cancer. Ann Intern Med. 150(12): JC6-4, JC6-5, 2009.

14. Canfield, S.E.: ACP Journal Club. Periodic screening with prostate-specific antigen testing reduced mortality from prostate cancer. Ann Intern Med. 150(12): JC6-5, JC6-4, 2009.

15. Canfield, S.E.: Annual screening for prostate cancer did not reduce mortality from prostate cancer. Evid Based Med. 14(4):104-105, 2009.

16. Canfield, S.E.: Periodic screening with prostate-specific antigen testing reduced mortality from prostate cancer. Evid Based Med. 14(4):104-105, 2009.

17. Canfield, S.E., Dahm, P.,The Evidence-Based Urology Working Group: Evidence based urology in practice: incorporating patient values in evidence-based clinical decision making. BJU Int. 105(1):4-5, 2009.

18. Frieben, R.W., Lin, H.C., Hinh, P.P., Berardinelli, F., Canfield, S.E., Wang, R.: The impact of minimally invasive surgeries for the treatment of symptomatic benign prostatic hyperplasia on male sexual function: a systematic review. Asian J Androl. 12(4):500-8, 2010.

19. MacDonald, S.L., Canfield, S.E., Fesperman, S.F, and Dahm, P.: Assessment of the methodological quality of systemic reviews published in the urological literature from 1988 to 2008. J Urol, 184:648-653, 2010

20. Canfield, S.E., Sultan, S., Dahm, P. and The Evidence-Based Urology Working Group: Evidence-based urology in practice: randomized controlled trials stopped early for benefit. BJU Int, 106(7):962-963, 2010.

21. Canfield, S.E. and Dahm, P.: Introduction to a new series: advanced topics in evidence-based urological oncology. Urologic Oncology, 29(4):446, 2011.

22. Lavallée, L.T., Montori, V.M., Canfield, S.E., Breau, R.H.: Advanced topics in evidence-based urological oncology: surrogate endpoints. Urol Oncol, 29(4):447-453, 2011.

23. Scales, C.D. and Canfield, S.E.: Advanced topics in evidence-based urological oncology: using results of a subgroup analysis. Urol Oncol, 29(4):462-466, 2011.

24. Canfield, S.E. and Dahm, P.: Rating the quality of evidence and the strength of recommendations using GRADE. World Journal of Urology, 29(3): 311-317, 2011.

25. Dahm, P., Kang, D., Stoffs, T.L., Canfield, S.E.: Recovery of erectile function after robotic prostatectomy: Evidence Based Outcomes. Urol Clin North Am,38(2): 95-103, 2011.

26. Canfield, S.E.: ACP Journal Club. Radical prostatectomy reduced mortality and disease progression over the long term more than watchful waiting in early prostate cancer. Ann Intern Med, 155 (2):JC1-2, 2011.

27. Dhir, R.R., Lin, H.C., Canfield, S.E., Wang, R.: Combination therapy for erectile dysfunction: an update review. Asian J Androl, 13(3):382-390, 2011.

28. Hinh, P. and Canfield, S.E.: Sample size matters: a guide for urologists. Indian Journal of Urology, 27(4):503-507, 2011.

29. Chan, A.A., Canfield, S.E., Wang, R.: Health-related quality of life outcomes in Scandinavian patients after radical prostatectomy or watchful waiting: a critical appraisal. Asian J Androl, Epub ahead of print. 2011

C. Invited Articles (Reviews, Editorials, etc) in Journals

1. Canfield, S.E.: Screening and prostate-cancer mortality in a randomized european study. Practical Reviews in Urology, 25(8), Audio Review, 2009.

2. Canfield, S.E.: Are cancer-related decision aids effective? A systematic review and meta-analysis. Practical Reviews in Urology, 25(8),2, 2009.

3. Canfield, S.E.: Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomized phase III trial. Practical Reviews in Urology, 25(8),3, 2009.

4. Canfield, S.E.: Mortality results from a randomized prostate-cancer screening trial. Practical Reviews in Urology, 25(8),Audio Review, 2009.

5. Canfield, S.E.: Quality of life in patients with locally advanced prostate cancer given endocrine treatment with or without radiotherapy: 4-year followup of SPCG-7/SFUO-3, an open label, randomized, phase III trial. Practical Reviews in Urology, 25(12),Audio Review, 2009.

6. Canfield, S.E.: Molecular markers can predict prostate cancer mortality. Practical Reviews in Urology, 25(12),Audio Review, 2009.

7. Canfield, S.E.: An easy prediction of urinary incontinence duration after retropubic radical prostatectomy based on urine loss the first day after catheter withdrawal. Practical Reviews in Urology, 25(12),2, 2009.

8. Canfield, S.E.: Randomized phase II trial of first-line treatment with Sorafenib versus Interferon Alfa-2a in patients with metastatic renal cell carcinoma. Practical Reviews in Urology, 25(12),3, 2009.

9. Canfield, S.E.: Duration of androgen suppression in the treatment of prostate cancer. Practical Reviews in Urology, 26(2),Audio Review, 2009.

10. Canfield, S.E.: Phase III postoperative Adjuvant Radiotherapy after radical prostatectomy compared with radical prostatectomy alone in pT3 prostate cancer with postoperative undetectable prostate-specific antigen: ARO96-02/AUO AP 09/95. Practical Reviews in Urology, 26(2),Audio Review, 2009.

11. Canfield, S.E.: Selective inhibition of CYP17 with Abiraterone Acetate is highly active in the treatment of castration-resistant prostate cancer. Practical Reviews in Urology, 26(2),2, 2009

12. Canfield, S.E.: Risk of bilateral renal cell cancer. Practical Reviews in Urology, 26(2),3, 2009.

13. Canfield, S.E.:Is Statin use associated with prostate cancer aggressiveness?
Practical Reviews in Urology, 26(6).Audio Review, 2009.

14. Canfield, S.E.: Adjuvant therapy with oral Sodium Clodronate in locally advanced and metastatic prostate cancer: Long-term overall survival results from the MRC PR04 and PR05 randomized controlled trials. Practical Reviews in Urology, 26(6).Audio Review, 2009.

15. Canfield, S.E.: Comorbidity, body mass index, and age and the risk of nonprostate-cancer-specific mortality after a postradiation prostate-specific antigen recurrence. Practical Reviews in Urology, 26(6).2, 2009.

16. Canfield, S.E.: Multinational,double-blind, phase III study of Prednisone and either Satraplatin or placebo in patients with castrate-refractory prostate cancer progressing after prior chemotherapy: the SPARC trial. Practical Reviews in Urology, 26(6).3, 2009.

17. Canfield, S.E.: The rate of secondary malignancies after radical prostatectomy versus external beam radiation therapy for localized prostate cancer: a population-based study on 17,845 patients. Practical Reviews in Urology, 26(8), Audio Review, 2010.

18. Canfield, S.E.: Randomized phase III trial on Gemcitabine versus Mytomicin (sic) in recurrent superficial bladder cancer: evaluation of efficacy and tolerance. Practical Reviews in Urology, 26(8).Audio Review, 2010.

19. Canfield, S.E.: Low quality of evidence for robot-assisted laparoscopic prostatectomy: results of a systematic review of the published literature. Practical Reviews in Urology, 26(8).2, 2010.

20. Canfield, S.E.: Mortality in Men with localized prostate cancer treated with brachytherapy with or without neoadjuvant hormone therapy. Practical Reviews in Urology, 26(8).3, 2010.

21. Canfield, S.E.: Chronic kidney disease after nephroureterectomy for upper tract urothelial carcinoma and implications for the administration of perioperative chemotherapy. Practical Reviews in Urology, 26(10).4, 2010.

22. Canfield, S.E.: Overall survival analysis of a phase II randomized controlled trial of a poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer. Practical Reviews in Urology, 26(10).5, 2010.

23. Canfield, S.E.: Effect of Dutasteride on the Risk of Prostate Cancer. Practical Reviews in Urology, 26 (10),Audio Review, 2010.

24. Canfield, S.E.: Systematic review of the clinical effectiveness and cost-effectiveness of photodynamic diagnosis and urine biomarkers (FISH, ImmunoCyt, NMP22) and cytology for the detection and follow-up of bladder cancer. Practical Reviews in Urology, 26 (10),Audio Review, 2010.

25. Canfield, S.E.: Management of urethral recurrence after orthotopic urinary diversion. Practical Reviews in Urology, 26 (12),2,2010.

26. Canfield, S.E.: Durable oncologic outcomes after radiofrequency ablation. Practical Reviews in Urology, 26 (12),3,2010.

27. Canfield, S.E.: Can we better select patients with metastatic renal cell carcinoma for cytoreductive nephrectomy? Practical Reviews in Urology, 26 (12),4, 2010.

28. Canfield, S.E.: Soft tissue surgical margin status is a powerful predictor of outcomes after radical cystectomy: A Multicenter Study of More Than 4,400 Patients. Practical Reviews in Urology, 26 (12),5, 2010.

29. Canfield, S.E.: Phase 3 trial of everolimus for metastatic renal cell carcinoma final results and analysis of prognostic factors. Practical Reviews in Urology, 26 (12),6, 2010.

30. Canfield, S.E.: Outcomes in localized prostate cancer: national prostate cancer register of Sweden follow-up study. Practical Reviews in Urology, 26 (12),7, 2010.

31. Canfield, S.E.: Baseline PSA as a predictor of prostate cancer - specific mortality over the past 2 decades. Practical Reviews in Urology, 26 (12),8, 2010.

32. Canfield, S.E: Risk of thromboembolic diseases in men with prostate
cancer: results from the population-based PCBaSe Sweden. Practical Reviews in Urology, 26 (12),9, 2010.

33. Canfield, S.E.: Baseline PSA as a predictor of prostate cancer-specific mortality over the past 2 decades: Duke University experience. Practical Reviews in Urology, 27 (4), Audio Review, 2010.

34. Canfield, S.E.: Outcomes in localized prostate cancer: National prostate cancer register of Sweden follow-up study. Practical Reviews in Urology, 27 (4), Audio Review, 2010.

35. Canfield, S.E.: Phase 3 trial of Everolimus for metastatic renal cell carcinoma: Final results and analysis of prognostic factors. Practical Reviews in Urology, 27 (4),1,2010.

36. Canfield, S.E.: Risk of thromboembolic diseases in men with prostate
cancer: results from the population-based PCBaSe Sweden. Practical Reviews in Urology, 27 (4),2, 2010.

37. Canfield, S.E.: Does prostatectomy have a role in advanced disease? Practical Reviews in Urology, 27 (6), Audio Review, 2010.

38. Canfield, S.E.: Common meds can reduce PSA. Practical Reviews in Urology, 27 (6), Audio Review, 2010.
39. Canfield, S.E.: ET for prostate cancer – do risks outweigh benefits? Practical Reviews in Urology, 27 (6), 1, 2010.

40. Canfield, S.E.: New nomogram is more powerful for predicting UTCC. Practical Reviews in Urology, 27 (6), 2, 2010.
41. Canfield, S.E.: The end for PSA? Practical Reviews in Urology, 27(8), Audio Review, 2011.

42. Canfield, S.E.: PSA at age 60 may predict your future. Practical Reviews in Urology, 27(8), Audio Review, 2011.

42. Canfield, S.E.: PSA screening – good for healthy men. Practical Reviews in Urology, 27(8),2,2011.

44. Canfield, S.E.: Delays in bladder cancer diagnosis may increase mortality. Practical Reviews in Urology, 27(8),3, 2011.

45. Canfield, S.E.: Levels of efidence ratings in the urological literature: an assessment of interobserver agreement. BJU Int, Editorial, 4, 2009

46. Canfield, S.E.: Active surveillance may be safe for intermediate-risk prostate cancer. Practical Reviews in Urology, 27(10), Audio Review, 2011.

47. Canfield, S.E.: Older age should not determine Prostate Cancer Treatment. Practical Reviews in Urology, 27(10), Audio Review, 2011.

48. Canfield, S.E.: Death of the DRE? Practical Reviews in Urology, 27(10), 1, 2011.

49. Canfield, S.E.: Medicare cuts funding, improves care! Practical Reviews in Urology, 27(10), 2, 2011.

50. Canfield, S.E.: Prostate cancer screening made simple. Practical Reviews in Urology, 27(12). Audio Review, 2011.

51. Canfield, S.E.: New option may prevent SREs in metastatic prostate cancer. Practical Reviews in Urology, 27(12), Audio Review, 2011.

52. Canfield, S.E.: Bladder cancer is not better with blue. Practical Reviews in Urology, 27(12), 16, 2011.

53. Canfield, S.E.: Chemotherapy instead of radiotherapy for stage I seminoma. Practical Reviews in Urology, 27(12), 17, 2011.

54. Canfield, S.E.: Radical prostatectomy reduced mortality and disease progression over the long term more than watchful waiting in early prostate cancer. ACP Journal Club, 154(7), web based publication, 2011.

55. Canfield, S.E.: PSA predicts for bone metastasis in castrate-resistant prostate cancer. Practical Reviews in Urology, 28 (2), Audio Review. 2011.

56. Canfield, S.E.: Carefully consider comorbid conditions in prostate cancer patients. Practical Reviews in Urology, 28 (2), Audio Review, 2011.

57. Canfield, S.E.: Are prostate cancer screening guidelines moving too fast? Practical Reviews in Urology, 28 (2), 1. 2011.

58. Canfield, S.E.: Beware of prostate biopsy mismatch. Practical Reviews in Urology. 28 (2), 2. 2011.

59. Canfield, S.E.: Radical prostatectomy improves survival over watchful waiting. Practical Reviews in Urology, 28 (6), Audio Review, 2011.

60. Canfield, S. E.: Hormones are good with radiation for intermediate-risk prostate cancer. Practical Reviews in Urology, 28 (6), Audio Review, 2011.

61. Canfield, S.E.: Resect the mets in RCC. Practical Reviews in Urology, 28 (6), 10.1, 2011.

62. Canfield, S.E.: Secondary hormonal therapy extends survival. Practical Reviews in Urology, 28 (6), 10.6, 2011.

63. Canfield, S.E.: What is the most accurate way to predict erectile function after prostate cancer tx? Practical Reviews in Urology. 28(10): Audio Review, 2012.

64. Canfield, S.E.: Vitamin E causes prostate cancer! Practical Reviews in Urology. 28(10): Audio Review, 2012.

65. Canfield, S.E.: Prostate Cancer reduces quality of life. Practical Reviews in Urology. 28(10): 10.6, 2012.

66. Canfield, S.E.: NSAIDs increase the risk of renal cell carcinoma. Practical Reviews in Urology. 28(10): 10.6, 2012.

D. Chapters

1. Canfield, S.E. (Ed.): Commonly used medications, in Gomella LG, and Lefor AT(Ed.) Surgery On Call, second edition, Appleton and Lange, Stamford, CT, 1996.

2. Dahm, P., Neuberger, M., and Canfield, S.E.: Evidence-Based Approach to the Surgical Literature. Essentials and Updates in Urologic Oncology, Nova Science Publishers, Inc., In Press.

 

Contact Information Steven E. Canfield M.D.

Steven E. Canfield M.D.

Associate Professor
Division of Urology
Department of Surgery

 

E-mail: Steven.Canfield@uth.tmc.edu
Assistant: Dorothy Stradinger
Office Address:
6431 Fannin Street
Suite 6.018
Houston, TX 77030

Office Phone: 713-500-7337
Office Fax: 713-500-7319

For an appointment, call:
832-325-7280